Israel: These 37 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Israel
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Israel: These 37 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can QUTENZA (capsaicin) generic drug versions launch?
Generic name: capsaicin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: Israel Patent 171,249
Patent Title: THERAPEUTIC PATCH WITH POLYSILOXANE MATRIX COMPRISING CAPSAICIN
QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.
This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA
See drug price trends for QUTENZA.
The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.
When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch?
Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Israel Patent 171,519
Patent Title: COMPOSITIONS FOR AFFECTING WEIGHT LOSS
CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and sixty patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE
See drug price trends for CONTRAVE.
The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.
When can PREVYMIS (letermovir) generic drug versions launch?
Generic name: letermovir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Israel Patent 171,513
Patent Title: SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PEROPERTIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR PREPARATION
PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has eighty-five patent family members in forty-five countries.
See drug price trends for PREVYMIS.
The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.
When can OMONTYS (peginesatide acetate) generic drug versions launch?
Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: Israel Patent 171,782
Patent Title: PEPTIDE DIMERS WHICH COMPRISE POLYETHYLENE GLYCOL THAT BIND TO THE ERYTHROPOIETIN RECEPTOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.
This drug has one hundred and fourteen patent family members in thirty-four countries.
The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
When can MAYZENT (siponimod fumaric acid) generic drug versions launch?
Generic name: siponimod fumaric acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Israel Patent 171,683
Patent Title: תרכובות מדכאות חיסון, תכשירים רפואיים המכילים אותן ושימושן בהכנת תרופות לטיפול (Immunosuppressant compounds, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for therapy)
MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has one hundred and forty patent family members in thirty-nine countries.
See drug price trends for MAYZENT.
The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.
When can JANUMET (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?
Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Israel Patent 172,563
Patent Title: PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET
See drug price trends for JANUMET.
The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
When can JANUMET XR (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?
Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Israel Patent 172,563
Patent Title: PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR
See drug price trends for JANUMET XR.
The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
When can JANUVIA (sitagliptin phosphate) generic drug versions launch?
Generic name: sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Israel Patent 172,563
Patent Title: PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA
See drug price trends for JANUVIA.
The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.
When can JUVISYNC (simvastatin; sitagliptin phosphate) generic drug versions launch?
Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Israel Patent 172,563
Patent Title: PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC
The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.
When can ORIAHNN (COPACKAGED) (elagolix sodium,estradiol,norethindrone acetate; elagolix sodium) generic drug versions launch?
Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Israel Patent 172,833
Patent Title: PYRIMIDINE-2,4-DIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.
This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)
The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.
When can ORILISSA (elagolix sodium) generic drug versions launch?
Generic name: elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Israel Patent 172,833
Patent Title: PYRIMIDINE-2,4-DIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA
See drug price trends for ORILISSA.
The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Israel Patent 172,746
Patent Title: תולדות (תיאו)קרבמואיל-ציקלוהקסאן כאנטגוניסטים של קולטן d3/d2 ((thio)carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists)
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR
See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.
When can RYZODEG 70/30 (insulin aspart; insulin degludec) generic drug versions launch?
Generic name: insulin aspart; insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Israel Patent 172,980
Patent Title: תולדות אינסולין, תכשירים רוקחיים המכילים אותן ושימושים בהן (Insulin derivatives, pharmaceutical compositions comprising them and uses thereof)
RYZODEG 70/30 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30
The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.
When can TRESIBA (insulin degludec) generic drug versions launch?
Generic name: insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Israel Patent 172,980
Patent Title: תולדות אינסולין, תכשירים רוקחיים המכילים אותן ושימושים בהן (Insulin derivatives, pharmaceutical compositions comprising them and uses thereof)
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA
See drug price trends for TRESIBA.
The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.
When can XULTOPHY 100/3.6 (insulin degludec; liraglutide) generic drug versions launch?
Generic name: insulin degludec; liraglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Israel Patent 172,980
Patent Title: תולדות אינסולין, תכשירים רוקחיים המכילים אותן ושימושים בהן (Insulin derivatives, pharmaceutical compositions comprising them and uses thereof)
XULTOPHY 100/3.6 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6
The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.
When can PRADAXA (dabigatran etexilate mesylate) generic drug versions launch?
Generic name: dabigatran etexilate mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Israel Patent 173,885
Patent Title: אתיל-3-[ ( 2- { 4- ( הקסילאוקסיקרבונילאמינו-אימינו-מתיל)-פנילאמינו]-מתיל}-1-מתיל -h1- בנזימידאזול-5- קרבוניל)-פירידין-2-יל-אמינו]-חומצה פרופיונית אתיל אסטר מתאן סולפונאט בצורתו הגבישית ii,תכשירי רוקחות המכילים אותו, והשימוש בו להכנת תכשירי רוקחות המתאימים למניעה לאחר ניתוח של פקקת ורידים עמוקים ולמניעת שבץ ותהליכים להכנתו (Ethyl-3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1- methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate in crystalline form ii, pharmaceutical composition comprising it and uses thereof for preparing pharmaceutical compositions which are suitable for the post-operative prophylaxis of deep vein thrombosis and the prevention of stroke and process for the preparation thereof)
This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA
See drug price trends for PRADAXA.
The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.
When can JEVTANA KIT (cabazitaxel) generic drug versions launch?
Generic name: cabazitaxel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Israel Patent 174,240
Patent Title: DIMETHOXY DOCETAXEL ACETONE SOLVATE AND METHOD FOR THE PREPARATION THEREOF
JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.
This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT
The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.
When can DUETACT (glimepiride; pioglitazone hydrochloride) generic drug versions launch?
Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: Israel Patent 174,201
Patent Title: SOLID PREPARATION COMPRISING A PIOGLITAZONE LAYER AND A LAYER COMPRISINIG GLIMEPIRIDE AND POLYSORBATE 80
DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT
See drug price trends for DUETACT.
The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.
When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?
Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: Israel Patent 175,529
Patent Title: טטראהידרוביאופטרין (4bh) או באופו אפשרי צורת המלח שלו עבור שימוש בטיפול של מטופל עם פנילקטונוריה (pku) (Tetrahydrobiopterin (bh4) or optionally a salt form thereof for use in the treatment of a subject with phenylketonuria(pku))
KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN
See drug price trends for KUVAN.
The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.
When can XARELTO (rivaroxaban) generic drug versions launch?
Generic name: rivaroxaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Israel Patent 175,860
Patent Title: שיטה ליצור תכשיר רוקחות מוצק למתן פומי (Method for the production of a solid, orally applicable pharmaceutical composition)
This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO
See drug price trends for XARELTO.
The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Israel Patent 176,416
Patent Title: תולדות פרוסטגלנדין ניטרואוקסי, תכשירים רוקחיים המכילים אותן, והשימוש בהן להכנת התרופה לטיפול בגלוקומה או לחץ תוך-עיני (Prostaglandin nitrooxy derivatives, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for treating glaucoma or ocular hypertension)
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Israel Patent 191,141
Patent Title: תרכובות הטרוציקליות ותכשירי רוקחות המכילים אותן (Heterocyclic compounds and pharmaceutical compositions containing the same)
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.
This drug has four hundred and fifty patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Israel Patent 222,784
Patent Title: תכשירים המכילים מאפנני הובלת קסטות מקושרות atp לשימוש בטיפול או הפחתת ציסטיק פיברוזה (Compositions comprising heterocyclic modulators of atp binding cassette transporters for use in treating or ameliorating cystic fibrosis)
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.
This drug has four hundred and fifty patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can EPANOVA (omega-3-carboxylic acids) generic drug versions launch?
Generic name: omega-3-carboxylic acids
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: Israel Patent 177,462
Patent Title: כפסול ג'לטין רך המכיל חומצה שמנית אומגה-3-רב-לא-רוויה (Soft gelatin capsule comprising omega-3-polyunsaturated fatty acid)
EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.
This drug has eighty-four patent family members in forty countries.
The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.
When can RUKOBIA (fostemsavir tromethamine) generic drug versions launch?
Generic name: fostemsavir tromethamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Israel Patent 177,945
Patent Title: PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS
RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.
This drug has thirty-nine patent family members in thirty countries.
See drug price trends for RUKOBIA.
The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.
When can RUKOBIA (fostemsavir tromethamine) generic drug versions launch?
Generic name: fostemsavir tromethamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Israel Patent 211,961
Patent Title: פרודראגים של תרכובות אנטיויראליות של פיפרזין ופיפרידין מותמר (Prodrugs of piperazine and substituted piperidine antiviral agents)
RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.
This drug has thirty-nine patent family members in thirty countries.
See drug price trends for RUKOBIA.
The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Israel Patent 177,043
Patent Title: GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Israel Patent 218,714
Patent Title: GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Israel Patent 177,043
Patent Title: GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Israel Patent 218,714
Patent Title: GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can IMPLANON (etonogestrel) generic drug versions launch?
Generic name: etonogestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Israel Patent 177,970
Patent Title: X-RAY VISIBLE DRUG DELIVERY DEVICE
IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.
This drug has thirty-two patent family members in twenty-six countries.
The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?
Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Israel Patent 177,829
Patent Title: MEDICATION DISPENSING APPARATUS WITH SPRING-DRIVEN LOCKING FEATURE ENABLED BY ADMINISTRATION OF FINAL DOSE
This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO
See drug price trends for FORTEO.
The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.
When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?
Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Israel Patent 178,510
Patent Title: תכשיר רב-פאזי למניעת היריון המבוסס על אסטרוגן טבעי (Multi-phase contraceptive preparation based on a natural estrogen)
This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA
See drug price trends for NATAZIA.
The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Israel Patent 178,152
Patent Title: 4-[HYDROXY(DIPHENYL)METHYL]-1-{2-[PHENYLMETHYL)OXY]ETHYL}-1-AZONIABICYCLO[2.2.2] OCTANE BROMIDE USEFUL FOR TREATING MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED DISEASES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
This drug has one hundred and seventy-seven patent family members in thirty-nine countries.
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Israel Patent 178,822
Patent Title: אמידים@@-@פנילאמינו-קווינזולין-6-יל, תכשירים רפואיים המכילים אותם, ושימושם בהכנת תרופות לטיפול בהפרעות פרוליפרטיביות (4-phenylamino-quinazolin-6-yl-amides, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for the treatment of proliferative disorders)
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety patent family members in forty-seven countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Israel Patent 179,020
Patent Title: PEPTIDE-BASED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES THEREOF IN THE PREPARATION OF MEDICAMENTS
KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Israel Patent 183,607
Patent Title: תכשירים רפואיים המכילים פפטיד אפוקסי קטון כמעכב פרוטאוזום וציקלודקסטרין מותמר ושימושם בהכנת תרופות (Pharmaceutical compositions comprising a peptide epoxy ketone proteasome inhibitor and a substituted cyclodextrin and uses thereof in the preparation of medicaments)
KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Israel Patent 214,776
Patent Title: תרכובות מבוססות פפטיד (Peptide-based compounds)
KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Israel Patent 246,171
Patent Title: תהליכים להכנת תרכובות מבוססות פפטיד (Processes for the preparation of peptide-based compounds)
KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Israel Patent 178,878
Patent Title: מתקן משאף (Inhaler device)
This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Israel Patent 178,878
Patent Title: מתקן משאף (Inhaler device)
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can CAPRELSA (vandetanib) generic drug versions launch?
Generic name: vandetanib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Israel Patent 178,928
Patent Title: PHARMACEUTICAL COMPOSITIONS COMPRISING ZD6474 OR A PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF
CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.
This drug has one hundred and forty-two patent family members in forty-three countries.
See drug price trends for CAPRELSA.
The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Israel Patent 179,454
Patent Title: COATED TABLET FORMULATION COMPRISING SAXAGLIPTIN AND METHOD FOR PREPARING THE SAME
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Israel Patent 218,117
Patent Title: טבליה המכילה סאקסאגליפטין ומספר שכבות ציפוי (Tablet comprising saxagliptin and multiple coating layers)
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Israel Patent 179,454
Patent Title: COATED TABLET FORMULATION COMPRISING SAXAGLIPTIN AND METHOD FOR PREPARING THE SAME
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Israel Patent 218,117
Patent Title: טבליה המכילה סאקסאגליפטין ומספר שכבות ציפוי (Tablet comprising saxagliptin and multiple coating layers)
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.